Outcomes of curative (chemo)radiotherapy for patients with non-p16 positive head and neck squamous cell carcinoma who are borderline for curative treatment.
adult comorbidity evaluation-27
borderline curability
elderly
head and neck cancer
squamous cell carcinoma
Journal
Journal of medical imaging and radiation oncology
ISSN: 1754-9485
Titre abrégé: J Med Imaging Radiat Oncol
Pays: Australia
ID NLM: 101469340
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
18
08
2019
accepted:
31
10
2019
pubmed:
11
2
2020
medline:
4
2
2021
entrez:
11
2
2020
Statut:
ppublish
Résumé
Appropriate selection of head and neck squamous cell cancer (HNSCC) patients for curative treatment is difficult, and it is a very understudied issue. The aim of this study was to review the outcomes of curative intent treatment in non-p16 positive HNSCC patients assessed as having borderline curability. A single institution retrospective review of the clinical outcomes of non-p16 positive HNSCC patients with borderline curability. Predefined criteria for borderline curability were as follows: (i) T4 and/or N3 disease; or (ii) ECOG status ≥2; or (iii) age ≥75 years. A total of 114 patients were identified. A total of 56 had N3/T4, 32 were >ECOG 2 and 57 were >75 years. A total of 29 had two or more borderline curability criteria. Progression-free survival rate (PFS) at 1 and 2 years was 72% (95% confidence interval (CI), 63-79) and 53% (95% CI, 43-62), respectively. Overall survival (OS) at 1 and 2 years was 76% (95% CI, 67-83) and 61% (95% CI, 51-69), respectively. On multivariable analysis, the only independent prognostic factor for OS was the adult comorbidity evaluation-27 (ACE-27) grade (HR 1.4; 95% CI, 1.1-1.8; P = 0.018). Patients with borderline curability criteria treated with curative intent achieved good PFS and OS. ACE-27 was an important prognostic factor in this population.
Identifiants
pubmed: 32037733
doi: 10.1111/1754-9485.12995
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
271-278Informations de copyright
© 2020 The Royal Australian and New Zealand College of Radiologists.
Références
Solem CT, Kwon Y, Shah RM, Aly A, Botteman MF. Systematic review and benchmarking of Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) in oncology. Expert Rev Pharmacoecon Outcomes Res 2018; 18: 245-53.
Denis F, Garaud P, Bardet E et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22: 69-76.
Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78.
Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-8.
Team RC. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, 2015.
McDowell L, Collins M, Kleid S, Rischin D, Corry J. T4 squamous cell carcinoma of the oral tongue without mandibular involvement: surgery or chemoradiotherapy? Oral Surg Oral Med Oral Pathol Oral Radiol 2014; 117: 163-9.
Corry J, Peters LJ, Costa ID et al. The 'QUAD SHOT'-a phase II study of palliative radiotherapy for incurable head and neck cancer. Radiother Oncol 2005; 77: 137-42.
Tiong A, Corry J. Head and neck. In: Handbook of Palliative Radiation Therapy. Demos Medical Publishing, New York, NY, 2016; 99-117.
Egelmeer AG, Velazquez ER, de Jong JM et al. Development and validation of nomogram for prediction of survival and local control in laryngeal carcinoma patients treated with radiotherapy alone: a cohort study based on 994 patients. Radiother Oncol 2011; 100: 108-115.
Fakhry C, Zhang Q, Nguyen-Tan PF et al. Development and validation of nomogram predictive of overall and progression-free survival in patients with oropharyngeal cancer. J Clin Oncol 2017; 35: 4057-65.
Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 1980; 45: 2220-4.
Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291: 2441-7.
Hall SF, Rochon PA, Streiner DL, Paszat LF, Groome PA, Rohland SL. Measuring comorbidity in patients with head and neck cancer. Laryngoscope 2002; 112: 1988-96.
Datema FR, Ferrier MB, van der Schroeff MP, Baatenburg de Jong RJ. Impact of comorbidity on short-term mortality and overall survival of head and neck cancer patients. Head Neck 2010; 32: 728-36.
The National Academies of Science, Engineering, and Medicine. Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis. The National Academies Press, Washington, DC, 2013.
Australian Government. 2015 Intergenerational Report: Australian in 2055. The Treasury of Australian Government, Canberra, Australia, 2015.
Pignon JP, Ie Maitre A, Maillard E, Bourhis J, MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update of 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14.
Huang SH, O’Sullivan B, Waldron J et al. Patterns of care in elderly head-and-neck cancer radiation oncology patients: a single-center cohort study. Int J Radiat Oncol Biol Phys 2011; 79: 46-51.
Pignon T, Horiot JC, Van den Bogaert W, Van Glabbeke M, Scalliet P. No age limit for radical radiotherapy in head and neck tumours. Eur J Cancer. 1996; 32A: 2075-81.